HIF2a inhibitors for the treatment of VHL disease.
Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA, USA.
Ana Martins
AM
Metelo
Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA, USA.
Haley
H
Noonan
Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA, USA.
Othon
O
Iliopoulos
D000818:Animals; D051792:Basic Helix-Loop-Helix Proteins / Q000037:antagonists & inhibitors*; D004195:Disease Models, Animal; D006801:Humans; D000860:Hypoxia; D007674:Kidney Diseases / Q000188:drug therapy* / Q000235:genetics*; D010100:Oxygen / Q000737:chemistry; D012333:RNA, Messenger / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D051794:Von Hippel-Lindau Tumor Suppressor Protein / Q000235:genetics*; D015027:Zebrafish; D000099162:Endothelial PAS Domain-Containing Protein 1
D051792:Basic Helix-Loop-Helix Proteins; D010100:Oxygen; D012333:RNA, Messenger; D016212:Transforming Growth Factor beta; D042461:Vascular Endothelial Growth Factor A; D051794:Von Hippel-Lindau Tumor Suppressor Protein; D000099162:Endothelial PAS Domain-Containing Protein 1; C497446:VHL protein, human
HIF2a inhibitors; VHL; hypoxia; renal cancer